Biotherapeutic products represent a new therapeutic revolution in disease treatment and are by far the fastest-growing segment of the pharmaceutical industry – yet the recent biosimilar guidelines issued by the World Health Organization (WHO) are myopic, inconsistent or vague about some well-established scientific issues Biosimilar products include recombinant proteins and hormones, monoclonal antibodies (mAbs), cytokines, […] Continue reading ->